Related Experiment Video
Updated: Jul 5, 2025
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Predictive Panel for Immunotherapy in Low-Grade Glioma.
Qingqing Lv1, Zhaoyu Zhang1, Haijuan Fu1
1Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China; The Key Laboratory of Carcinogenesis of the Chinese Ministry of Health, The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, China.
This study identifies three immune subtypes in low-grade glioma (LGG). Patients with the IS2 subtype are best suited for immunotherapy, with five specific markers predicting treatment success.
Area of Science:
- Neuro-oncology
- Immunology
- Genomics
Background:
- Low-grade glioma (LGG) treatment relies on surgery, radiotherapy, and chemotherapy, facing limitations like side effects and resistance.
- Immunotherapy offers promise for LGG but is often impeded by the tumor microenvironment and limited tumor antigen expression.
Purpose of the Study:
- To identify optimal patient candidates for immune checkpoint therapy in LGG.
- To explore immune characteristics and identify predictive markers for immunotherapy efficacy in LGG.
Main Methods:
- Integrated RNA sequencing data and clinical information for consistent cluster analysis.
- Utilized gene set enrichment, UMAP, mutation correlation, TIMER, and TIDE analyses.
- Analyzed homologous recombination repair (HRR) gene mutations and immune cell infiltration across subtypes.
Main Results:
- Identified three distinct immune subtypes (IS1, IS2, IS3) with segregated HRR gene mutations.
- The IS2 subtype exhibited high HRR mutations and upregulated immune checkpoint genes, indicating increased immunogenicity and suitability for immunotherapy.
- Discovered five predictive markers (NAMPT, SLC11A1, TNC, VIM, SPP1) for immune checkpoint blockade (ICB) efficacy in LGG, associated with prognosis.
Conclusions:
- Established three reliable immune subtypes for LGG, with IS2 patients being ideal candidates for immunotherapy.
- Validated NAMPT, SLC11A1, TNC, VIM, and SPP1 as predictive markers for ICB efficacy in LGG.
- Provided a framework for immunotherapy selection and prognostic prediction in LGG patients.
